Podcasts about opposed

Matthew 2:1-23

AP Washington correspondent Sagar Meghani reports President Trump is unloading on conservative Supreme Court justices who voted against his tariffs -- including two of his appointees.

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Learn more about your ad choices. Visit megaphone.fm/adchoices

Title: Opposed but Joyful Preacher: Mark Dever Series: The Church Begins Passage: Acts 5:1-42

Watkins was a founder of the political organization Freedom, Inc. and one of the Kansas City Council's first two Black members. He was a vocal opponent of Highway 71 — although parts of the parkway were eventually named after him. An event at the Kansas City Public Library on Sunday, Feb. 15, will remember his full life and legacy.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textHannah and Laura are so excited to be celebrating the release of Adam Bassett's new book, Copper Skin, Oaken Lungs, by chatting with the author himself! Adam talks about his inspirations for this unique, YA fantasy, blending magic with technology, and finding joy in difficult times. You can follow Adam Bassett online at:Website: Adam Bassett | Author, Illustrator, DesignerInstagram: Adam Bassett (@adamcbassett) • Instagram photos and videosThreads: Adam Bassett (@adamcbassett) • Threads, Say moreBluesky: Adam Bassett (@adamcbassett.com) — Bluesky**This video is the inspiration for Copper Skin, Oaken Lungs: Tautumeitas - Bur Man Laimi | Latvia

Evangelist Dan shares Biblical teaching on faith, healing, prosperity, freedom from sin, and living a victorious life. Your life will be transformed by the power of God's Word.

In the U.S., there are about 100,000 monkeys, baboons, and other primates living in captivity to support scientific research. About 5,000 of them are at OHSU’s Oregon National Primate Research Center. That’s where researchers do experiments on monkeys to try to get clear data about things like cannabis use during pregnancy, and to find cures for diseases like HIV. Animal rights activists have argued for decades that the center should be closed. And they’re gaining momentum with support from Oregon’s governor and some lawmakers. In addition, scientists who oppose using animals in research argue that the practice has become obsolete and is hindering, not helping the effort to find cures.    Today, we’re bringing back our episode about the Oregon National Primate Research Center because just a few weeks ago in January, OHSU’s board of directors had a meeting to hear about what it would take to close the center or significantly reduce the size of its primate population.    OPB health reporter Amelia Templeton shares what she learned from a visit to the Oregon National Primate Research Center and conversations with a lot of smart people on all sides of this complex topic.    Don’t forget to check out our many podcasts, which can be found on any of your favorite podcast apps: Hush Timber Wars Season 2: Salmon Wars Politics Now Think Out Loud And many more! Check out our full show list here.

In this message, Ben unpacks the profound truth that "Grace is opposed to earning, but not effort," tackling the common spiritual struggle of feeling the need to perform for God's love. He shares his personal journey of moving away from a "spiritual grind" to finding real freedom in his faith, challenging the idea that we're responsible for earning a percentage of our own grace. Discover how to re-center your identity as a beloved son or daughter of God, and learn two simple, life-changing shifts—slowing down your approach to Bible reading and adopting a practice of continual "Help, Thanks, Wow" prayer—that have re-energized his relationship with Jesus and can do the same for you.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Learn more about your ad choices. Visit megaphone.fm/adchoices

Hometown Radio 01/28/26 3:30p: Dr. Gene Nelson remains opposed to the S. Higuera Traffic Project

-Meta has faced some serious questions about how it allows its underage users to interact with AI-powered chatbots. Most recently, internal communications obtained by the New Mexico Attorney General's Office revealed that although Meta CEO Mark Zuckerberg was opposed to the chatbots having "explicit" conversations with minors, he also rejected the idea of placing parental controls on the feature. -Snap's augmented reality glasses business will now be its own entity, with the company establishing Specs Inc. as a wholly owned subsidiary. It will enable Snap to more easily secure investors and partnerships for its wearables, as well as to grow Specs into a distinct brand while running it within Snap Inc. -LinkedIn is leaning into the rise of vibe coding by allowing users to show off their proficiency with various AI coding tools directly on their profiles. The company is partnering with Replit, Lovabl, Descript and Relay.app Learn more about your ad choices. Visit podcastchoices.com/adchoices

A walk through of the book of Acts with Pastor Mat - Jan 27, 2026 Apologetics, Debate, Bible Discussions, Evangelism, and much more Discerning the fruits of the Spirit vs the fruits of self - Mark 7:5-23 "The mystic fruit bowl" - https://youtu.be/kw7QiLQMQ_M?si=356Fx_r9ohUeTLwjThe Deity of Jesus Christ and the Gospel of Salvation - https://www.youtube.com/live/gquqBQIL_0U?si=7zmPLi1X0CcW-v7f(Discussing discipleship) Bible study on Luke 9:60-62 "Let the dead bury the dead" - https://www.youtube.com/live/BkWtkOrEs-Q?si=y-zyqNGfWi3kzVu2To know more on how to be saved, what are the requirements and such, please see our playlist on the Gospel and Eternal Security (assurance of salvation) - https://youtube.com/playlist?list=PL3pJdCnnwrEeCQOCTTmDW1GjUYxpd44DG&si=_rT-lThl0klHt5Cd Our Ministries Website - https://christiancoffeetime.ca/ 1John 5:20) "And we know that the Son of God is come, and hath given us an understanding, that we may know him that is true, and we are in him that is true, even in his Son Jesus Christ. This is the true God, and eternal life." - Intro Music: A Flourish by Niya is licensed under a Creative Commons License.https://creativecommons.org/licenses/...Support by RFM - NCM: https://bit.ly/2xGHypM -

Guest: Professor Richard Carwardine. Carwardine explains that President-elect Lincoln did not view Republicans as overly aggressive, positioning himself as a constitution-respecting centrist rather than a radical. Lincoln opposed slavery's expansion but acknowledged its constitutional protection where it already existed, believing the South was misled by elites and would eventually return to the Union. Ironically, Lincoln and Buchanan, though political opposites, worshiped at the same Washington church, sharing an old-school Presbyterian background.1861 ST. MICHAEL'S, CHARLESTON SOUTH CAROLINA

Grace is central to our faith yet its meaning is often confused. Mixed messages can leave us in a tug-of-war between “doing nothing” and “trying harder” to earn God's favor. What is grace actually and how does it affect our daily apprenticeship to Jesus?Tune in for this episode of Soul Talks as Bill and Kristi unpack what they've learned about grace from Dallas Willard. Discover how grace can go beyond “undeserved merit” and become fuel for your life, relationships, and ministry. You can set aside pretending, presuming, and pushing to respond to grace and join God's activity in everything you do! (If you want to go deeper into the insights we gained from Dallas Willard, we invite you to join us on a retreat or train to become a spiritual director with Soul Shepherding. You can learn more by following the links below.)Resources for this Episode:Your Best Life in Jesus' Easy Yoke: Rhythms of Grace to De-Stress and Live EmpoweredAttend a Soul Shepherding RetreatEarn a Certificate in Spiritual DirectionDonate to Support Soul Shepherding and Soul Talks

Coastal First Nations in B.C. say their stance on a pipeline from Alberta to B.C. has not changed following a meeting with Prime Minister Mark Carney on Tuesday. Power & Politics hears from one of those nations and a former Alberta energy minister.

For the latest on this our Europe editor, Tony Connelly.

Nicole Coppola didn't grow up searching for Jesus. She actively rejected Christianity, mocked it, and wanted nothing to do with God.What happened next wasn't emotional, trendy, or explainable — it was personal, specific, and impossible for her to dismiss.Raised around spirituality but deeply opposed to Christianity, Nicole spent years pushing back against faith, questioning truth, and resisting the idea of a personal God. After losing her mother at a young age and her sister shortly after, she searched for meaning, certainty, and purpose — but found only frustration, unanswered questions, and resistance where faith was concerned.Then, unexpectedly, everything began to shift.In this conversation, Nicole shares how God broke through her opposition in ways she never anticipated — through moments she couldn't explain away, a sudden spiritual awakening, and a series of deeply personal encounters that forced her to confront the reality of a God who is not distant, symbolic, or passive, but present, personal, and willing to meet people even when they are standing in opposition.This is not a story about becoming religious. It's a story about awakening — about discovering that God is real, personal, and able to reach people who never intended to believe.If you've ever questioned Christianity, dismissed faith because of religious tradition, or felt resistance toward God — or if you know someone who has — this conversation may speak directly to where you are.---------------------------Follow Nicole's Instagram here ⇨ https://www.instagram.com/carrideswithchrist/--------------------------✟ Donate to A Stronger Faith here ⇨ https://www.astrongerfaith.org/give--------------------------✟ Recommend a guest for us here ⇨ https://www.astrongerfaith.org/contact--------------------------✟ CONNECT WITH US! ⇨ Website: https://www.astrongerfaith.org/ ⇨ YouTube: https://bit.ly/asfmyoutube ⇨ Instagram: https://www.instagram.com/astrongerfaith/ ⇨ TikTok: https://www.tiktok.com/@astrongerfaith ⇨ Facebook: https://www.facebook.com/astrongerfaith------------------------------------✟ If you need prayer or deliverance, or if you would like to join us as a prayer partner, please visit our prayer resources page at https://www.astrongerfaith.org/prayer.✟ If you are looking for a good faith-building book, visit our recommended books page at https://www.astrongerfaith.org/books.

And [Mary and Joseph] brought [Jesus] up to Jerusalem to present Him to the Lord …. Now there was a man in Jerusalem, whose name was Simeon …. And it had been revealed to him by the Holy Spirit that he would not see death before he had seen the Lord's Christ. … he [Simeon] took Him [Jesus] up in his arms and blessed God …. And Simeon blessed them and said to Mary His mother, “Behold, this Child is appointed for the fall and rising of many in Israel, and for a sign that is opposed ….” (Luke 2:22b, 25a, 26, 28a, 34)

An effort to ban fox hunting in Ireland will be voted down in the Dáil later today, which is seen by some to be a step back in animal welfare. Fianna Fáil, Fine Gael and Sinn Féin are all set to oppose the ban.To discuss this decision, Ciara Doherty is joined by Independent Minister of State, Michael Healy Rae.

WBBM political editor Geoff Buchholz reports on a new budget proposal presented as an alternate to Mayor Brandon Johnson's controversial corporate "head tax."

The war in Ukraine has pushed defence issues to the top of the agenda in Germany, where the federal government has confirmed that a military call-up will return as early as next year. All young men born from 2008 onwards will have to register and undergo medical exams, starting in 2027. To begin with, service will be voluntary. But if the ranks of Germany's armed forces are not filled fast enough, authorities reserve the right to bring back compulsory conscription, which was suspended in 2011. This prospect is awakening old ghosts: war, the militarisation of youth and conscientious objection. Our correspondents report.

WBBM political editor Geoff Buchholz reports on a new budget proposal presented as an alternate to Mayor Brandon Johnson's controversial corporate "head tax."

WBBM political editor Geoff Buchholz reports on a new budget proposal presented as an alternate to Mayor Brandon Johnson's controversial corporate "head tax."

Support us as we expand our challenge to our broken media here: https://www.patreon.com/owenjones84 or here: https://kofi.com/owenjonesSupport this show http://supporter.acast.com/the-owen-jones-podcast. Hosted on Acast. See acast.com/privacy for more information.

Political Horseshoe: Convergence of Left and Right on Interventionism — Veronique de Rugy — de Rugy describes the political "horseshoe" theory wherein ideologically opposed left and right political movements converge on preferences for expansive government intervention and managed economy policies. de Rugy documents that while left and right factions blame different villains—wealth inequality versus immigration—both now support agricultural subsidies, protectionist tariffs, and direct state economic intervention. de Rugy emphasizes that both extremes have systematically abandoned classical free-market principles in favor of comprehensive managed economy frameworks emphasizing state control and industrial policy direction. 1910

PREVIEW — Veronique de Rugy — The Political Horseshoe: Converging Discontent. de Rugy explains the political "horseshoe" theory, which posits that ideologically opposed extremes—the far Left and far Right—converge in their fundamental conviction that the United States is pursuing a catastrophic trajectory requiring comprehensive government intervention and systemic restructuring. de Rugy documents that both ideological poles perceive the existing political-economic order as fundamentally irreparably corrupted or unjust, generating agreement across the ideological spectrum regarding the necessity of radical systemic transformation despite divergent visions regarding post-transformation governance structures and resource allocation mechanisms. 1955

See omnystudio.com/listener for privacy information.

You're listening to American Ground Radio with Louis R. Avallone and Stephen Parr. This is the full show for December 2, 2025. 0:30 President Trump has just pulled off what may be the boldest constitutional power play in modern history—nullifying every executive order, proclamation, and pardon stamped with Joe Biden’s auto-pen. With one move, Trump flips the script and forces Democrats into a corner: if they want those Biden-era actions back—like Fauci’s pardon—they’ll have to sue him and testify under oath about Biden’s actual mental capacity. It’s shrewd. It’s historic. And it puts the whole auto-pen scandal center stage. 9:30 Plus, we cover the Top 3 Things You Need to Know. The Trump Administration fired 8 immigration judges in New York City this week. Costco has filed a lawsuit seeking to be reimbursed for tariffs. One third of the commercial Drivers licenses issued by the state of Minnesota to foreign citizens was illegal and violated federal law. 12:30 Get Prodovite Plus from Victory Nutrition International for 20% off. Go to vni.life/agr and use the promo code AGR20. 13:00 Why does the word socialism sound so warm and friendly—when the system itself is anything but? We break down how the Left sells “social justice” and “social programs” with feel-good language, while real human connection gets replaced with government control. And why, in the end, the most “social” system might actually be capitalism. 16:00 We got a question in for our American Mamas, Teri Netterville and Kimberly Burleson. Michael Douglas and Catherine Zeta-Jones are furious with CNN after their son, Dylan, went on air and got absolutely schooled by Scott Jennings. Now the Hollywood power couple is blaming the network. We ask the American Mamas if they have a right to be upset with CNN for “setting him up to fail.” The Mamas ask a simple question: He’s 25… so who really set him up? We get into NEPO babies, media bubbles, and what happens when activism meets actual debate. Tune in—this conversation gets real. 23:00 Today we’re getting into mindsets—prosperity versus poverty—and why President Trump’s new “Trump accounts” are lighting a fire under the private sector. Michael and Susan Dell just dropped a staggering $6 billion to seed investment accounts for millions of American kids, and it’s sparking a bigger conversation: What happens when real innovators—not Washington—decide to bet on the next generation? We break down the difference between handouts and true investment, the power of compound growth, and why this is prosperity thinking in action. 26:00 We break down the left’s latest outrage—accusing Secretary of War Pete Hegseth of war crimes after the U.S. Navy took out a cartel-run drug boat in the Caribbean. The media is pushing a narrative that doesn’t even match its own reporting, and we’re unpacking every contradiction. We dig into President Trump’s Day One executive order labeling violent drug cartels as foreign terrorist organizations, the legal authority behind military action on the high seas, and why the AUMF from 2001 still matters today. Plus, we look at the staggering reality: drug cartels are killing the equivalent of 30 9/11s every year through narcotics flowing into America—yet some politicians are more upset about taking out cartel operatives than stopping the carnage. 32:00 Get Performlyte from Victory Nutrition International for 20% off. Go to vni.life/agr and use the promo code AGR20. 32:30 We take a break from the heavy headlines to highlight just how far the American media has fallen—courtesy of The Washington Post, which decided the burning issue of our time is… bored pets. Yep. Front-page analysis on your cat’s emotional frustration while the country faces real crises. 35:30 We dive into a major move from Secretary of Agriculture Brooke Rollins, who’s announcing a full review of USDA programs to ensure benefits go only to U.S. citizens. Some call it common sense. Others call it controversial. We break down the clash: taxpayer dollars, strained safety nets, and the growing fight between states and the federal government over who gets what—and who pays for it. We're cutting through the noise, pushing past the political spin to get to the heart of the issue: limited resources, runaway costs, and a national conversation that’s quickly shifting from compassion to crisis. 39:30 A new poll shows Americans are turning on the idea of a four-year degree—only 33% now say college is worth the price tag. What happened? Higher education is losing its shine, from sky-high tuition fueled by government subsidies to campuses that feel more political than practical. People are looking at the cost compared to what they can make, and they're saying, "whoa." Follow us: americangroundradio.com Facebook: facebook.com / AmericanGroundRadio Instagram: instagram.com/americangroundradioSee omnystudio.com/listener for privacy information.

This Super Full Moon in Gemini lights up the mind and nervous system with extra clarity. Opposed by the Sun in Sagittarius conjunct the Great Attractor, it draws a luminous line between the stories we tell ourselves and the deep, unseen call of soul-purpose. Under this lunation, old Virgo-wrought vows around control, perfection, and worth through service are being exposed in the moonlight — while a Piscean current of trust, surrender, and intuitive flow invites us to soften. Link to join my email list for the Lunar Herbal Alchemy Intensive: www.everythingisenergyapothecary.com/contact Link to the blog post for this episode: www.everythingisenergyapothecary.com/podcast/gemini-full-moon-release-trust-reorientation

Acts 19 – Andy Littleton

Acts 19 – Andy Littleton

5/8. William Randolph Hearst Breaks with Roosevelt over Tax Policy — David Pietrusza — Newspaper and radio magnate William Randolph Hearst, who initially opposed FDR in 1932, became progressively disaffected as Rooseveltmoved leftward and proposed substantial tax increases on wealthy Americans. FDR explicitly discussed the political utility of throwing wealthy opponents, particularly Hearst, "to the wolves" as a populist rallying point. Hearst, who had met with Hitler in 1934, remained a formidable though complicating political force that FDR deemed necessary to neutralize or isolate. 1936

Despite the expectation of opposition, Jesus' kingdom of witnesses will advance according to God's plan, built on the apostolic foundation.

We never opposed the 10 percent royalty under the former Akufo-Addo government as a parliamentary minority - Alhaji Collins Dauda clarifies on the Ghana lithium agreement.

See omnystudio.com/listener for privacy information.

VLOG Nov 12: Sudan genocide liability of BNP Paribas spun by bank, book: https://www.amazon.com/dp/B0FWTSDM7LGhislaine Maxwell book blocking alert removed from/by Threads [!] https://www.threads.com/@innercitypressinsta/post/DQ9axHTDoUS TD Bank closings and UBS foray into US opposed; UN cover up in South Sudan

The news of Texas covered today includes:Our Lone Star story of the day: A Texas-sized embarrassment took place this week with some Texas National Guard troops being pulled from deployment for not meeting mission standards. Secretary of War Hegseth has lowered the gauntlet over fitness standards in the military but this is not a new issue. Back in the regular session of the Texas Legislature, a bill was pushed to help with a real fitness problem for Texas National and State Guard members but was opposed by the Texas Military Department – seems to me they now have egg on their faces.Ammon Blair, a senior fellow at the Texas Public Policy Foundation, joins us to talk about the issue, what was in the bill, and why the brass opposed it.Our Lone Star story of the day is sponsored by Allied Compliance Services providing the best service in DOT, business and personal drug and alcohol testing since 1995.Attorney General Paxton successfully uses the Texas Health and Safety code to frustrate Malcolm Tanner's effort to recruit people to Loving County for a political takeover.Much change has been made but the folks at the Alamo Trust are still woke leftists lying in wait to destroy Texas heritage. Land Commissioner Dawn Buckingham goes after the woke bunch at the Trust after those folks posted an “indigenous peoples” day message.Listen on the radio, or station stream, at 5pm Central. Click for our radio and streaming affiliates.www.PrattonTexas.com

What do you do if you're excited about learning how to trade in the stock market but your spouse has reservations?   Today we're going to be talking about how to integrate the skill set of trading into the family, and providing some suggestions about how to share your excitement for trading with your spouse.   Here at TRADEway we teach families how to take advantage of one of the most dynamic markets in history, the US stock market.   But you can't incorporate something like stock trading into your household unless there is a shared mission between husband and wife.   So what do you do if you want to give stock trading a try, but you're not sure if your spouse is “all in” on it? That's what we're going to talk about today.  

“But some men spoke against Stephen. They did not agree with what he taught people. These men were from one of the Jewish meeting places in Jerusalem. People called them, ‘The Group of Free Men'. These men were Jews from the cities called Cyrene and Alexandria. Some of them were from towns in Cilicia and Asia. They began to argue with Stephen.”Acts 6:9 EASY

8. Blockade vs. Invasion: Ending the Pacific War and Post-War Command AUTHOR: Professor Craig Symonds BOOK TITLE: Nimitz at War: Command Leadership from Pearl Harbor to Tokyo Bay Nimitz and King opposed the planned invasion of the Japanese home islands (Operation Downfall), arguing that a strict naval blockade, executed primarily by submarines, combined with bombing, would force surrender. They calculated that an invasion would cost hundreds of thousands of American lives and millions of Japanese lives, given the culture of fighting to the death. Nimitz was informed about the secret development of a special weapon (the atomic bomb) in March 1945 to ensure targets were reserved. After the war ended, Nimitz was the logical candidate for Chief of Naval Operations (CNO), though he faced opposition from the aviation community (Towers). He accepted a two-year term as CNO. Admiral Spruance declined high command, instead choosing to become President of the Naval War College to teach future officers the lessons learned in the Pacific War.

The remarks come after pressure from the administration led ABC to suspend late-night TV host Jimmy Kimmel. Mr Kimmel made comments about the Charlie Kirk murder suspect, saying Trump supporters had tried to "characterise this kid as anything other than one of them".Also, we speak to Omar Barghouti who co-founded the worldwide movement to isolate Israel, through boycott, sanctions and divestment; and we head to Moscow to meet some of the musicians competing in Intervision, the Kremlin's counterpoint to Eurovision.(Photo: President Donald Trump speaks to reporters aboard Air Force One on his return from a state visit in Britain, 18 September, 2025. Credit: Kevin Lamarque/Reuters)

Wow! The questions in this episode are deep, but I'm here for it. I loved answering your questions that ranged from the reality of homeschooling boys who are on the move (it was a common theme for this one), homeschooling specific questions, and we ended with a question that brought tears to my eyes. Enjoy getting my point of view on these and when you have a question, I'd love to hear it! ♥ Leigh   ASK YOUR QUESTION TO BE ANSWERED ON THE PODCAST: https://bit.ly/homeschoolquestion   DESIGN YOUR FAMILY'S UNIQUE HOMESCHOOL THAT YOU'LL LOVE! https://littlebylittlehomeschool.com/blueprint   CREATE YOUR HOMESCHOOL FAMILY'S HOME TASK SYSTEM https://www.littlebylittlehomeschool.com/tidyhome    GET EXCLUSIVE MENTORSHIP WITH LEIGH https://littlebylittlehomeschool.com/mentorship   LITTLE BY LITTLE HOMESCHOOL CONFERENCE TICKETS:  https://littlebylittlehomeschool.com/conference   SIMPLIFY YOUR MEAL PLANNING https://littlebylittlehomeschool.com/meal     Website -  https://www.littlebylittlehomeschool.com Newsletter -  https://littlebylittlehomeschool.myflodesk.com/subscribe Community - https://www.facebook.com/groups/homeschoollifestylecommunity Instagram - https://www.instagram.com/littlebylittlehomeschool/ Facebook - https://www.facebook.com/littlebylittlehomeschool/   Listen to these related episodes: 311. The Approach You Need To Teach Boys And Girls Differently    235. Raising Boys In Today's Culture With Durenda Wilson: How A Homeschool Mom Meets The Challenges Through All The Ages    310. My Best Advice For Raising Boys Of All Ages And What To Do With Bad Attitudes In The Teen Years     172. 5 Ways to Help Instill Faith in Your Homeschool Child and Why It Is Worth the Time